Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

ecent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Biogen (Nasdaq: BIIB - Free Report ... Biotechnology (NYSE: PBYI - Free Report ), AbbVie (NYSE: ... CELG - Free Report ). Today, Zacks is ...
(Date:7/31/2014)... , July 31, 2014 Vermillion, Inc. (NASDAQ: ... women,s health, will hold a conference call on Thursday, August ... for the second quarter ended June 30, 2014. Financial results ... call. Vermillion,s Chairman, President and CEO James ... and answer period. Date: Thursday, August 14, 2014 ...
(Date:7/31/2014)... 31, 2014 TB Alliance, a not-for-profit ... faster and affordable treatments, announced the appointment of ... External Affairs. Mr. Brock comes to TB Alliance ... Donor Relations for WWF International (formerly known as ... Brock will guide the TB Alliance,s resource development, ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... , , , BOSTON, Sept. ... financial gift to the Harvard Stem Cell Institute (HSCI) Seminar Series ... Terms of the gift were not disclosed. , , ... stem cell science community in which pioneers in the national and ...
... , SAN DIEGO, Sept. 1 ... in adult stem cell research and manufacturing, announced today that it ... & Drug Branch to manufacture stem cells for human clinical trials. ... law and the applicable provisions of the Code of Federal Regulations. ...
Cached Medicine Technology:Stemgent Announces Sponsorship of Harvard Stem Cell Institute Seminar Series; 2Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2
(Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
(Date:7/31/2014)... July 31, 2014 Developer Jamestown, L.P., ... on its Ponce City Market project in Atlanta’s Old ... Roebuck & Company building into best-in-class office, housing, and ... reviewed Jamestown’s experience with their construction webcam service to ... Jamestown wanted a construction camera for monitoring ...
(Date:7/31/2014)... July 31, 2014 Leelanau Peninsula’s newest winery, ... 3, 2014 at 7788 East Horn Road in Lake Leelanau. ... Trail , Aurora Cellars is the 25th winery along the ... the popular wine tour events, making its trail event debut ... 2014. , Owners David and Faye Mathia opened the ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering ... Systematic Review of Sexual Satisfaction . The ... Journal of Clinical and Health Psychology. , This CE ... to have accurate information about sexual satisfaction so that ... The material provides a systematic review of 197 research ...
Breaking Medicine News(10 mins):Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... (May 14, 2012) - A team of international scientists has ... duct cancer, a deadly type of liver cancer. By identifying ... are paving the way for better understanding of how bile ... Nature Genetics . Bile Duct Cancer, or Cholangiocarcinoma, is ...
... S.C. - Clemson University researcher Julia Frugoli has received ... four-year grant from the National Science Foundation to continue ... with each other to control their growth and development. ... Clemson University,s College of Agriculture, Forestry & Life Sciences, ...
... , MONDAY, May 14 (HealthDay News) -- Feeding tubes ... according to a new study. The finding challenges the ... bed sores or helps promote their healing in this group ... The researchers did not look at how feeding tubes ...
... May 14, 2012 Persistent Systems (BSE & ... (OPD) services, and the Translational Genomics Research Institute (TGen) ... management system called Bio4D. Initial versions of the ... and genomic research, have been used at TGen in ...
... Storrs HealthDay Reporter , MONDAY, May 14 (HealthDay ... or running while toting a bottle, a pacifier or a ... nationwide survey, researchers estimated that more than 45,000 visits to ... 3 years old were because of injuries related to using ...
... News) -- Doing more repetitions with less weight builds ... with heavy weights, a new Canadian study indicates. ... to the point of fatigue, according to the researchers ... how different combinations of weight loads and repetitions affected ...
Cached Medicine News:Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 2Health News:Scientists make breakthrough in bile duct cancer with discovery of new gene mutations 3Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2Health News:For Dementia Patients, Feeding Tubes May Increase Bed Sores 2Health News:New biospecimens management system in development 2Health News:Baby Bottles, Pacifiers, Sippy Cups Can Injure 2Health News:Baby Bottles, Pacifiers, Sippy Cups Can Injure 3Health News:With Weights, You Can Lighten Your Load 2
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
Medicine Products: